Stock listing

Helsinki:HRTIS Herantis Pharma PLC Osake

Home listing (Helsinki) of Herantis Pharma PLC

Follow Herantis Pharma PLC into a list and get an email when it puts out news.

Share price · OMXHEX:HRTIS

€1.33 EUR -0.07 (-5.0%)

Close on Nov 20, 2026

Past year -37.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€1.30 – €1.50 EURNov 20, 2026
Volume
26,041 sharesNov 20, 2026
Market cap
€35.25M EURAt the close on Nov 20, 2026 · price × 26.50M shares outstanding
52-week range
€1.05 – €2.87 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€40,800 EURMedian day 24,607 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Herantis Pharma PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Helsinki:HRTIS · Home€1.33 EUR-0.07 (-5.0%)26,041€1.49€1.50€1.302€1.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXHEX:HRTIS · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€1.33-0.07-5.0%€1.49€1.50€1.30226,041
€1.40+0.05+3.7%€1.388€1.40€1.36224,623
€1.350.000.0%€1.362€1.398€1.33421,758
€1.35+0.08+6.3%€1.272€1.388€1.27252,123
€1.27+0.052+4.3%€1.216€1.31€1.1545,581
€1.218-0.072-5.6%€1.288€1.294€1.21637,522
€1.29+0.172+15.4%€1.138€1.30€1.138127,908
€1.118-0.016-1.4%€1.13€1.134€1.0554,381
€1.134-0.034-2.9%€1.162€1.184€1.1327,065
€1.168-0.008-0.7%€1.194€1.194€1.1125,839
€1.176-0.01-0.8%€1.188€1.26€1.169,414
€1.186+0.006+0.5%€1.198€1.206€1.15416,432
€1.18-0.02-1.7%€1.20€1.20€1.11864,380
€1.20-0.034-2.8%€1.29€1.29€1.1727,832
€1.234-0.046-3.6%€1.26€1.26€1.23411,527
€1.28+0.114+9.8%€1.158€1.28€1.15841,785
€1.166+0.016+1.4%€1.138€1.174€1.1399,545
€1.15-0.076-6.2%€1.25€1.25€1.13250,997
€1.226-0.024-1.9%€1.248€1.248€1.2119,388
€1.25-0.016-1.3%€1.268€1.27€1.2513,091
€1.266-0.014-1.1%€1.33€1.33€1.2519,683
€1.28-0.016-1.2%€1.36€1.36€1.2714,249
€1.296-0.002-0.2%€1.296€1.298€1.2721,910
€1.298-0.062-4.6%€1.358€1.358€1.27437,796
€1.36+0.014+1.0%€1.36€1.37€1.34211,360
€1.346-0.016-1.2%€1.362€1.37€1.31634,236
€1.362+0.02+1.5%€1.342€1.362€1.33829,786
€1.342+0.004+0.3%€1.35€1.362€1.32812,773
€1.338-0.006-0.4%€1.42€1.42€1.3311,667
€1.344-0.056-4.0%€1.41€1.42€1.34411,859
€1.40+0.03+2.2%€1.372€1.40€1.34229,524
€1.37-0.048-3.4%€1.36€1.37€1.3241,046
€1.418+0.026+1.9%€1.392€1.428€1.34216,567
€1.392-0.03-2.1%€1.422€1.422€1.35819,043
€1.422+0.016+1.1%€1.38€1.428€1.3713,202
€1.406-0.02-1.4%€1.45€1.45€1.38211,750
€1.426+0.026+1.9%€1.40€1.448€1.37224,626
€1.400.000.0%€1.398€1.422€1.35426,860
€1.40+0.008+0.6%€1.398€1.40€1.3521,722
€1.392-0.008-0.6%€1.40€1.40€1.37221,941
€1.40+0.01+0.7%€1.404€1.41€1.3947,175
€1.39-0.01-0.7%€1.40€1.416€1.38418,696
€1.40+0.012+0.9%€1.392€1.41€1.3848,462
€1.388-0.022-1.6%€1.412€1.428€1.38434,905
€1.410.000.0%€1.412€1.412€1.3818,974
€1.41-0.02-1.4%€1.43€1.43€1.4060,102
€1.43-0.038-2.6%€1.458€1.462€1.42232,111
€1.468-0.01-0.7%€1.51€1.51€1.45414,196
€1.478-0.022-1.5%€1.50€1.522€1.45631,157
€1.50-0.03-2.0%€1.53€1.544€1.4660,971
€1.53-0.03-1.9%€1.56€1.582€1.52425,220
€1.56-0.036-2.3%€1.596€1.596€1.5426,407
€1.596+0.036+2.3%€1.56€1.598€1.5466,903
€1.56-0.002-0.1%€1.564€1.59€1.54212,308
€1.562-0.026-1.6%€1.57€1.586€1.5419,023
€1.588-0.048-2.9%€1.618€1.634€1.55413,973
€1.636-0.014-0.8%€1.65€1.66€1.62211,966
€1.65+0.03+1.9%€1.658€1.696€1.64820,408
€1.620.000.0%€1.638€1.68€1.6212,313
€1.62-0.07-4.1%€1.66€1.682€1.60624,590
€1.69+0.052+3.2%€1.652€1.69€1.65210,781
€1.638+0.106+6.9%€1.56€1.64€1.5627,497
€1.532+0.002+0.1%€1.592€1.626€1.53266,285
€1.53-0.16-9.5%€1.678€1.678€1.52687,493

Splits

1 split · OMXHEX:HRTIS · every price before a split is adjusted for it

DayRatioWhat
102-for-97Split
Ticker
Helsinki:HRTIS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Helsinki
Currency
EUR

What changed lately

Latest news

All Herantis Pharma PLC news

Herantis Pharma PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 17 in all · newest Aug 10, 2026 · oldest 2025
Decks
33 decks · latest September 2026

Where Herantis Pharma PLC is listed

ListingExchangeCountryCurrency
Helsinki:HRTIS · Home listing · This pageHelsinkiFinlandEUR
LS Exchange:A1158VLS ExchangeGermanyEUR
Lang & Schwarz:A1158VLang & SchwarzGermanyEUR

Valuation

Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€35.19M EUR
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Herantis Pharma PLC · OMXHEX:HRTISUS$38.69MUS$38.62Mn/an/an/an/an/an/an/a
Dogwood Therapeutics, Inc. · NASDAQ:DWTXUS$39.57MUS$34.74Mn/a347×n/a0.6×n/a0.0×0.79
Quratis Inc. · KRX:348080US$38.60MUS$29.66Mn/a36.2×n/a1.1×n/a0.0×n/a
Harvard Apparatus Regenerative Technology Inc · OTC:HRGNUS$38.54MUS$36.69Mn/a36.5×n/a73.8×−642.0%0.0×0.09
KoBioLabs, Inc. · KRX:348150US$38.47MUS$7.00Mn/a0.1×n/a1.8×−6.4%0.2×n/a
OSE Immunotherapeutics SA · EURONEXT:OSEUS$38.31MUS$52.28Mn/a18.2×n/a1.3×n/a1.3×n/a
Sprint Bioscience AB · OMXSTO:SPRINTUS$37.98MUS$28.86M5.1×2.1×3.7×4.3×54.4%0.0×n/a
Theralase Technologies Inc. · TSXV:TLTUS$37.89MUS$34.22Mn/a61.1×n/a7.9×−472.5%0.0×0.75
Connect Biopharma Holdings Limited · NASDAQ:CNTBUS$37.15MUS$18.16Mn/a4.9×n/a3.1×n/a0.0×0.93
Coiled Therapeutics PLC · LSE:COILUS$37.13MUS$30.46Mn/an/an/a0.6×n/a0.0×n/a
TaiRx, Inc. · TPEX:6580US$37.08MUS$28.62Mn/a33.8×n/a3.3×−793.3%0.0×n/a
Median of the othersUS$38.14MUS$30.06M5.1×33.8×3.7×2.4×−472.5%0.0×0.77

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
2.00 EUR · Analysts' mean
EPS, year to Dec 2026
-0.16 · 1 analyst

Team and board

Officers

OfficerRole
Antti VuolantoChief Executive Officer
Tone KvåleChief Financial Officer
Henri HuttunenChief Scientific Officer
Juha SavolaChief Medical Officer

Board

DirectorRole
Timo VeromaaMD, PhD, eMBA, Chairman of the Board
Aki PrihtiBoard member
Frans WuiteMD, MBA, Board Member
Hilde FurbergMSc, Board Member
Mats ThorénBoard member

Events

QuarterResultsShare move
Q4 2022Mar 2, 2023 · Before open+1.5%
Q2 2022Aug 25, 2022−9.3%
Q4 2021Mar 7, 2022−2.4%
Q2 2021Aug 26, 2021 · Before open−6.2%
Q4 2020Mar 3, 2021 · Before open−0.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck22 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck31 slidesJune 2026
Investor Presentation (October 2024)Investor deck24 slidesOctober 2024
FY2023 Earnings PresentationEarnings17 slidesMar 6, 2024
Technical Presentation (October 2023)Technical16 slidesOct 25, 2023
Investor Presentation (September 2023)Investor deck14 slidesSeptember 2023
Investor Presentation (January 2023)Investor deck12 slidesJan 26, 2023
Investor Presentation (May 2022)Investor deck17 slidesMay 2022
Investor Presentation (May 2022)Investor deck17 slidesMay 2022
Investor Presentation (May 2022)Investor deck17 slidesMay 2022
All 33 decks
DeckKindSlidesDate
Investor Presentation (March 2022)Investor deck18 slidesMarch 2022
Investor Presentation (November 2021)Investor deck30 slidesNovember 2021
Investor Presentation (September 2021)Investor deck24 slidesSeptember 2021
Investor Presentation (May 2021)Investor deck23 slidesMay 2021
Investor Presentation (December 2020)Investor deck28 slidesDec 16, 2020
TreatER webinar 2020Conference18 slidesNov 18, 2020
TreatER webinar 2020Conference14 slidesNov 18, 2020
TreatER Webcast (November 2020)Conference12 slidesNov 18, 2020
TreatER Webcast (November 2020)Conference13 slidesNov 18, 2020
Treat ER webinar (November 2020)Conference23 slidesNov 18, 2020
Technical Presentation (September 2020)Technical42 slidesSep 15, 2020
Danske Bank Small & Mid Cap Day, LSX Nordic, Pareto Securities 11th Healthcare Conference (September 2020)Conference12 slidesSep 3, 2020
Shareholder Meeting (April 2020)Shareholder meeting27 slidesApr 8, 2020
Investor Day (March 2020)Investor day26 slidesMar 24, 2020
Technical Presentation (February 2020)Technical23 slidesFeb 28, 2020
Vator Unicorn Summit, Stockholm 2019Conference20 slidesNov 27, 2019
RedEye Life Science Day, Stockholm 2019Conference20 slidesNov 19, 2019
Avanza Börsdag, Stockholm 2019Conference22 slidesNov 19, 2019
Shareholder Meeting (April 2019)Shareholder meeting29 slidesApr 11, 2019
LE&RN Online Symposium 2018Conference27 slidesJun 13, 2018
Shareholder Meeting (April 2018)Shareholder meeting29 slidesApr 11, 2018
Shareholder Meeting (April 2017)Shareholder meeting26 slidesApr 11, 2017
IPO Roadshow (May 2014)IPO roadshow17 slidesMay 12, 2014

Open Decks

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000000025.3K
Cost of revenue927.7K1.05M1.20M1.22M27.1K
Gross profit-928.0K-1.05M-1.20M-1.22M-1.80K
Research and development3.60M2.70M5.00M6.20M5.33M4.93M2.10M2.33M2.73M
Selling, general and administrative1.92M1.49M1.74M2.65M2.25M2.04M1.40M1.24M1.02M0
Operating income-6.39M-5.03M154.4K-7.99M-9.05M-8.07M-7.16M-4.87M-2.24M-4.42M
Depreciation and amortization5.03M0159.7K2.72M927.7K1.05M1.20M1.22M1.20M
EBITDA489154.4K-7.83M-6.33M-7.14M-6.11M-3.67M-1.02M-3.22M
Interest expense13.7K5.66K551.6K1.33M63.0K1.08M868.8K60.6K309.2K82.5K
Income before tax-6.62M-4.94M279.8K-9.32M-23.6M-9.15M-8.01M-4.18M-2.17M-4.42M
Income tax-11.33M308.4K1.08M868.8K-259.5K78.2K
Net income-6.62M-4.94M279.8K-9.32M-23.6M-9.15M-8.01M-4.18M-2.17M-4.42M
Earnings per share, basic-0.28-0.240.02-0.64-2.31-1.18-1.30-0.85-0.51-1.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents751.0K635.0K5.50M5.04M5.63M12.3M6.01M719.1K90.6K782.2K
Short-term investments1.85M1.50M985.2K955.0K985.2K985.2K985.2K1.47M5.31M2.05M
Receivables72.0K406.5K257.4K241.3K142.7K174.3K261.8K93.7K90.5K41.6K
Current assets2.67M2.57M6.75M6.23M6.76M13.5M7.26M2.29M5.51M2.89M
Property, plant and equipment0003.69K4.92K6.56K8.75K
Goodwill077.7K310.9K544.0K
Total assets2.67M2.57M6.75M6.23M6.92M16.4M11.1M7.15M11.6M10.2M
Accounts payable389.0K278.0K748.7K660.3K788.0K716.1K1.62M199.6K278.3K186.1K
Current liabilities912.0K634.0K1.99M1.90M1.89M2.89M2.01M1.36M1.46M613.0K
Long-term debt20.0K2.18M29.8K4.39M6.29M5.94M7.21M5.88M6.02M8.02M
Total debt3.45M30.0K34.8K4.54M4.69M7.21M7.21M6.39M6.57M8.12M
Total liabilities4.36M2.81M2.02M6.29M6.36M8.83M9.22M7.24M7.48M8.63M
Shareholders' equity-1.69M-243.0K4.73M-60.3K554.3K7.59M1.85M-89.3K4.09M1.57M
Shares outstanding23.6M20.2M17.2M14.7M10.2M7.77M6.14M4.92M4.22M4.33M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.10M-6.54M-4.64M-8.94M-9.93M-8.56M-5.96M-3.73M-2.60M-3.04M
Capital spending-6.10M0-4000000-10.4K
Free cash flow-6.10M-6.54M-4.64M-8.94M-9.93M-8.56M-5.96M-3.73M-2.60M-3.05M
Cash from investing-244.0K-474.0K607.1K-210.1K-1.05M3.69K3.69K7.17K-33-71.3K
Cash from financing6.46M2.15M4.50M8.56M4.03M14.9M10.8M508.6K5.17M395.9K
Share buybacks5.19M04.51M8.71M4.04M14.9M
Change in cash116.5K-4.87M467.2K-594.6K-5.90M6.33M4.81M-3.22M2.57M-2.71M

Open Financials

Cap table

Built by 6ix from Herantis Pharma PLC’s releases

Common shares
26,503,817
Fully diluted
26,503,817

Fully diluted

LineShares
Common shares26,503,817

Share count over time

CountShares
Nov 22, 202626,503,817

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aki PrihtiBoard member · Since at least Mar 30, 2026
Antti VuolantoChief Executive Officer · Since at least Aug 10, 2026
Frans WuiteMD, MBA, Board Member · Since at least Mar 30, 2026
Henri HuttunenChief Scientific Officer · Since at least Mar 30, 2026
Hilde FurbergMSc, Board Member · Since at least Mar 30, 2026
Juha SavolaChief Medical Officer · Since at least Aug 10, 2026
Mats ThorénBoard member · Since at least Mar 30, 2026
Timo VeromaaMD, PhD, eMBA, Chairman of the Board · Since at least Mar 30, 2026
Tone KvåleChief Financial Officer · Since at least Aug 10, 2026

Open People

Log in to ask 6ix AI your own questions about Herantis Pharma PLC.